Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.27
AMED's Cash to Debt is ranked lower than
55% of the 239 Companies
in the Global Medical Care industry.

( Industry Median: 0.36 vs. AMED: 0.27 )
Ranked among companies with meaningful Cash to Debt only.
AMED' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.35 Max: N/A
Current: 0.27
Equity to Asset 0.60
AMED's Equity to Asset is ranked higher than
69% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. AMED: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
AMED' s Equity to Asset Range Over the Past 10 Years
Min: -0.23  Med: 0.58 Max: 1
Current: 0.6
-0.23
1
F-Score: 6
Z-Score: 5.52
M-Score: -3.14
WACC vs ROIC
7.52%
-1.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -0.72
AMED's Operating margin (%) is ranked lower than
80% of the 235 Companies
in the Global Medical Care industry.

( Industry Median: 7.46 vs. AMED: -0.72 )
Ranked among companies with meaningful Operating margin (%) only.
AMED' s Operating margin (%) Range Over the Past 10 Years
Min: -32.02  Med: 6.92 Max: 15.25
Current: -0.72
-32.02
15.25
Net-margin (%) -0.24
AMED's Net-margin (%) is ranked lower than
75% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 4.79 vs. AMED: -0.24 )
Ranked among companies with meaningful Net-margin (%) only.
AMED' s Net-margin (%) Range Over the Past 10 Years
Min: -26.01  Med: 3.98 Max: 9.33
Current: -0.24
-26.01
9.33
ROE (%) -0.78
AMED's ROE (%) is ranked lower than
79% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 8.90 vs. AMED: -0.78 )
Ranked among companies with meaningful ROE (%) only.
AMED' s ROE (%) Range Over the Past 10 Years
Min: -54.77  Med: 8.54 Max: 20.95
Current: -0.78
-54.77
20.95
ROA (%) -0.46
AMED's ROA (%) is ranked lower than
75% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 3.78 vs. AMED: -0.46 )
Ranked among companies with meaningful ROA (%) only.
AMED' s ROA (%) Range Over the Past 10 Years
Min: -35.44  Med: 5.47 Max: 12.39
Current: -0.46
-35.44
12.39
ROC (Joel Greenblatt) (%) 15.15
AMED's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 17.56 vs. AMED: 15.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMED' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -327.41  Med: 77.02 Max: 233.27
Current: 15.15
-327.41
233.27
Revenue Growth (3Y)(%) -8.00
AMED's Revenue Growth (3Y)(%) is ranked lower than
87% of the 173 Companies
in the Global Medical Care industry.

( Industry Median: 7.60 vs. AMED: -8.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMED' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -23  Med: 5.10 Max: 35.1
Current: -8
-23
35.1
EPS Growth (3Y)(%) -67.70
AMED's EPS Growth (3Y)(%) is ranked lower than
99% of the 123 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. AMED: -67.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AMED' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.7  Med: 31.60 Max: 186.7
Current: -67.7
-67.7
186.7
» AMED's 10-Y Financials

Financials (Next Earnings Date: 2016-05-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

AMED Guru Trades in Q1 2015

Joel Greenblatt 39,534 sh (+69.32%)
Paul Tudor Jones 12,578 sh (-57.82%)
Jim Simons 67,601 sh (-67.78%)
» More
Q2 2015

AMED Guru Trades in Q2 2015

Steven Cohen 90,500 sh (New)
Joel Greenblatt 395,393 sh (+900.13%)
Jim Simons 117,200 sh (+73.37%)
Paul Tudor Jones Sold Out
» More
Q3 2015

AMED Guru Trades in Q3 2015

Paul Tudor Jones 7,757 sh (New)
Jim Simons 148,001 sh (+26.28%)
Steven Cohen 52,800 sh (-41.66%)
Joel Greenblatt 137,387 sh (-65.25%)
» More
Q4 2015

AMED Guru Trades in Q4 2015

Joel Greenblatt 345,912 sh (+151.78%)
Jim Simons 348,301 sh (+135.34%)
Steven Cohen 97,300 sh (+84.28%)
Paul Tudor Jones 6,400 sh (-17.49%)
» More
» Details

Insider Trades

Latest Guru Trades with AMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 26.32
AMED's Forward P/E is ranked lower than
88% of the 74 Companies
in the Global Medical Care industry.

( Industry Median: 16.81 vs. AMED: 26.32 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 4.26
AMED's P/B is ranked lower than
72% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 2.50 vs. AMED: 4.26 )
Ranked among companies with meaningful P/B only.
AMED' s P/B Range Over the Past 10 Years
Min: 0.5  Med: 1.98 Max: 4.34
Current: 4.26
0.5
4.34
P/S 1.36
AMED's P/S is ranked higher than
56% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.56 vs. AMED: 1.36 )
Ranked among companies with meaningful P/S only.
AMED' s P/S Range Over the Past 10 Years
Min: 0.19  Med: 0.79 Max: 2.28
Current: 1.36
0.19
2.28
PFCF 19.99
AMED's PFCF is ranked higher than
53% of the 114 Companies
in the Global Medical Care industry.

( Industry Median: 21.39 vs. AMED: 19.99 )
Ranked among companies with meaningful PFCF only.
AMED' s PFCF Range Over the Past 10 Years
Min: 2.95  Med: 10.52 Max: 87.98
Current: 19.99
2.95
87.98
POCF 16.00
AMED's POCF is ranked lower than
53% of the 153 Companies
in the Global Medical Care industry.

( Industry Median: 14.93 vs. AMED: 16.00 )
Ranked among companies with meaningful POCF only.
AMED' s POCF Range Over the Past 10 Years
Min: 2.02  Med: 6.46 Max: 23.15
Current: 16
2.02
23.15
EV-to-EBIT 171.42
AMED's EV-to-EBIT is ranked lower than
98% of the 179 Companies
in the Global Medical Care industry.

( Industry Median: 19.52 vs. AMED: 171.42 )
Ranked among companies with meaningful EV-to-EBIT only.
AMED' s EV-to-EBIT Range Over the Past 10 Years
Min: -177  Med: 7.20 Max: 2214.4
Current: 171.42
-177
2214.4
EV-to-EBITDA 58.88
AMED's EV-to-EBITDA is ranked lower than
92% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 13.44 vs. AMED: 58.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMED' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.8  Med: 6.55 Max: 65
Current: 58.88
-6.8
65
Current Ratio 1.00
AMED's Current Ratio is ranked lower than
68% of the 225 Companies
in the Global Medical Care industry.

( Industry Median: 1.36 vs. AMED: 1.00 )
Ranked among companies with meaningful Current Ratio only.
AMED' s Current Ratio Range Over the Past 10 Years
Min: 0.42  Med: 1.00 Max: 2.83
Current: 1
0.42
2.83
Quick Ratio 1.00
AMED's Quick Ratio is ranked lower than
63% of the 225 Companies
in the Global Medical Care industry.

( Industry Median: 1.27 vs. AMED: 1.00 )
Ranked among companies with meaningful Quick Ratio only.
AMED' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.00 Max: 2.75
Current: 1
0.4
2.75
Days Sales Outstanding 35.63
AMED's Days Sales Outstanding is ranked higher than
61% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 44.25 vs. AMED: 35.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.1  Med: 36.50 Max: 54.01
Current: 35.63
30.1
54.01
Days Payable 12.91
AMED's Days Payable is ranked lower than
86% of the 155 Companies
in the Global Medical Care industry.

( Industry Median: 42.56 vs. AMED: 12.91 )
Ranked among companies with meaningful Days Payable only.
AMED' s Days Payable Range Over the Past 10 Years
Min: 8.33  Med: 12.00 Max: 22.23
Current: 12.91
8.33
22.23

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 16.77
AMED's Price/Tangible Book is ranked lower than
92% of the 166 Companies
in the Global Medical Care industry.

( Industry Median: 3.57 vs. AMED: 16.77 )
Ranked among companies with meaningful Price/Tangible Book only.
AMED' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.2  Med: 6.08 Max: 29.62
Current: 16.77
0.2
29.62
Price/Projected FCF 2.02
AMED's Price/Projected FCF is ranked lower than
62% of the 85 Companies
in the Global Medical Care industry.

( Industry Median: 1.71 vs. AMED: 2.02 )
Ranked among companies with meaningful Price/Projected FCF only.
AMED' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.16  Med: 1.01 Max: 2.59
Current: 2.02
0.16
2.59
Price/Median PS Value 1.71
AMED's Price/Median PS Value is ranked lower than
84% of the 187 Companies
in the Global Medical Care industry.

( Industry Median: 1.04 vs. AMED: 1.71 )
Ranked among companies with meaningful Price/Median PS Value only.
AMED' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.22  Med: 0.69 Max: 2.37
Current: 1.71
0.22
2.37
Price/Peter Lynch Fair Value 0.71
AMED's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 45 Companies
in the Global Medical Care industry.

( Industry Median: 2.21 vs. AMED: 0.71 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
AMED' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.34  Med: 0.75 Max: 3.24
Current: 0.71
0.34
3.24
Earnings Yield (Greenblatt) (%) 0.60
AMED's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 223 Companies
in the Global Medical Care industry.

( Industry Median: 4.10 vs. AMED: 0.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMED' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 9.25 Max: 33.9
Current: 0.6
0.1
33.9
Forward Rate of Return (Yacktman) (%) 34.57
AMED's Forward Rate of Return (Yacktman) (%) is ranked higher than
93% of the 102 Companies
in the Global Medical Care industry.

( Industry Median: 11.10 vs. AMED: 34.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AMED' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7  Med: 40.80 Max: 109.3
Current: 34.57
7
109.3

More Statistics

Revenue(Mil) $1281
EPS $ -0.11
Beta0.48
Short Percentage of Float7.56%
52-Week Range $26.05 - 54.29
Shares Outstanding(Mil)33.33

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 1,456 1,530
EPS($) 1.73 2.01
EPS without NRI($) 1.73 2.01

Business Description

Industry: Health Care Providers » Medical Care
Compare:NAS:LPNT, LSE:NMC, BOM:508869, JSE:LHC, NYSE:CHE, NYSE:CYH » details
Traded in other countries:ADY.Germany,
Amedisys Inc was originally incorporated in Louisiana in 1982. Its operations were transferred to a Delaware corporation, which was incorporated in 1994; and became a publicly traded company in August of that year. The Company is a provider of low-cost home health services to the chronic, co-morbid, aging American population. The operations involve servicing patients through its two reportable business segments: home health and hospice. The home health segment delivers services in the homes of individuals who may be recovering from an illness, injury or surgery. Its hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Individuals with a terminal illness such as heart disease, pulmonary disease, dementia, Alzheimers, HIV/AIDS or cancer may be eligible for hospice care. The Company operates 41 home health care centers and five hospice care centers with care centers servicing the same markets, sold 19 home health care centers and one hospice care center and closed 10 home health care centers. The Companys operations are regulated by Federal, state and local authorities.
» More Articles for NAS:AMED

Headlines

Articles On GuruFocus.com
“Powerball” Ideas - Home Healthcare Companies: AFAM, GTIV, LHCG, AMED Jan 05 2012 
AMED: Investment Opportunity When the Price Hits an 8-Year Low Dec 27 2011 
Almost Family: The Magic Formula Stock is getting cheaper and cheaper Dec 11 2011 
Magic Formula Stock: Amedisys (AMED) Aug 05 2011 
Home Healthcare: Heavily Shorted long Opportunity May 30 2011 
Amedisys Inc (AMED) CFO Dale E Redman buys 1,000 Shares Aug 25 2010 
Amedisys Inc Reports Operating Results (10-Q) Aug 09 2010 
Amedisys Inc Reports Operating Results (10-Q) Apr 27 2010 
Amedisys Inc (AMED) Chairman of the Board William F Borne sells 25,000 Shares Feb 24 2010 
Amedisys Inc (AMED) Chairman of the Board William F Borne sells 12,500 Shares Dec 29 2009 

More From Other Websites
Amedisys Reports First Quarter Financial Results May 03 2016
5:34 pm Amedisys reports EPS in-line, beats on revs May 03 2016
Amedisys Reports First Quarter Financial Results May 03 2016
AMEDISYS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... May 03 2016
Q1 2016 Amedisys Inc Earnings Release - After Market Close May 03 2016
AMEDISYS INC Files SEC form 8-K, Entry into a Material Definitive Agreement May 02 2016
Amedisys Announces First Quarter Earnings Release and Conference Call Date Apr 26 2016
Amedisys Announces First Quarter Earnings Release and Conference Call Date Apr 26 2016
Amedisys Welcomes Three New Members To Its Board Of Directors Apr 26 2016
AMEDISYS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles... Apr 26 2016
Amedisys Welcomes Three New Members To Its Board Of Directors Apr 26 2016
ETF’s with exposure to Amedisys, Inc. : April 19, 2016 Apr 19 2016
Amedisys Poised To Help Baby Boomers ‘Age In Place’ Apr 18 2016
Amedisys Poised on Balanced Growth, Strategic Buyouts Apr 12 2016
Looking for a Growth Stock? Why it is Time to Focus on Amedisys (AMED) Apr 08 2016
Amedisys Announces Clinical Excellence in Speech Language Pathology Mar 31 2016
Amedisys Announces Clinical Excellence in Speech Language Pathology Mar 31 2016
Amedisys, Inc. partners with Strategic Healthcare Programs (SHP) for insights to help enhance... Mar 30 2016
ETF’s with exposure to Amedisys, Inc. : March 29, 2016 Mar 29 2016
Can The Uptrend Continue for Amedisys (AMED)? Mar 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK